Titan Medical (NASDAQ:TMDIF) versus InfuSystem (NYSE:INFU) Head-To-Head Comparison
by Scott Moore · The Cerbat GemTitan Medical (NASDAQ:TMDIF – Get Free Report) and InfuSystem (NYSE:INFU – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Risk and Volatility
Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Titan Medical and InfuSystem, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Titan Medical | 0 | 0 | 0 | 0 | 0.00 |
| InfuSystem | 0 | 1 | 2 | 2 | 3.20 |
InfuSystem has a consensus price target of $14.50, suggesting a potential upside of 56.93%. Given InfuSystem’s stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Titan Medical.
Institutional and Insider Ownership
0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by insiders. Comparatively, 11.4% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Titan Medical and InfuSystem”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Titan Medical | $17.63 million | 2.33 | $6.95 million | $0.05 | 7.20 |
| InfuSystem | $141.05 million | 1.33 | $870,000.00 | $0.26 | 35.54 |
Titan Medical has higher earnings, but lower revenue than InfuSystem. Titan Medical is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Titan Medical and InfuSystem’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Titan Medical | N/A | -82.31% | -51.47% |
| InfuSystem | 1.12% | 2.78% | 1.41% |
Summary
InfuSystem beats Titan Medical on 13 of the 15 factors compared between the two stocks.
About Titan Medical
Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.
About InfuSystem
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.